22Apr
21Apr
OmniLife Brings on Experienced Health Care Leader Dyan Bymark to Scale the Business for Growth and Expansion
OmniLife, a SaaS health technology integrated communication and care coordination platform for the organ transplantation and organ failure care continuum, has named Dyan Bymark Chief Commercial Officer. In her newly created role, she will lead the company’s product, marketing, and business development initiatives as well as support sales operations to drive sustainable growth and position OmniLife as a leader in the rapidly growing healthcare coordination market. Bymark brings more than 25 years of experience to OmniLife’s leadership team as a...
21Apr
NEW STUDY: ONLY ONE QUARTER OF U.S. ADULTS WILL HAVE CABLE TV IN A FEW YEARS
Pixability, the provider of software and insights for video advertising on YouTube and other leading connected TV (CTV) platforms, today announced the release of a new study — How We Watch Now: US Consumer Streaming Habits on YouTube and Other Connected TV Platforms. The study, based on a survey of more than 700 U.S. adults over 18, examined trends in traditional and connected TV viewership, along with content consumption preferences and use of major CTV streaming platforms. While 59% of...
21Apr
ANGEL CITY FOOTBALL CLUB X ARCHER ROOSE WINES PARTNERSHIP | ARCHER ROOSE
Today, Angel City Football Club (ACFC) announced Archer Roose Wines as the team’s Official Wine Partner. The partnership with the Boston-based luxury canned wine company stemmed from a shared value of supporting and elevating female trailblazers. Through the game-changing Angel City Sponsorship Model, in which 10% of every partnership is reallocated back into the LA community, ACFC and Archer Roose will benefit programs that promote inclusivity in sport. Read more >>
20Apr
Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease
Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD). NLY01, Neuraly’s lead development asset, is a glucagon-like peptide 1 receptor (GLP-1R) agonist that has been demonstrated to inhibit pathological activation of microglia by binding upregulated GLP-1R in animal models of neurodegenerative diseases such as PD. Read more >>
16Apr
Podcast 354: Laurel Taylor of FutureFuel.io and Sunil Sachdev of Fiserv
The guests on the Fintech One-on-One Podcast are Laurel Taylor, the CEO and founder of FutureFuel.io and Sunil Sachdev, the Head of Fintech at Fiserv. These two companies have partnered to tackle the student debt problem, by bringing tools, awareness, and scale in this unique partnership. In this podcast you will learn: How Laurel’s personal experience with student loan debt led to the founding of FutureFuel.io/Why Fiserv created a fintech group/Why it is important for Fiserv to tackle student loan...
14Apr
MoEngage Partners with Anti-Superficial Dating App S’More to Deliver Personalized Customer Engagement and Scale App Activity
S'More, the anti-superficial dating app that connects singles based on content instead of looks, has tapped insights-led customer engagement platform MoEngage to provide hyper-personalized experiences across mobile channels such as push notifications and in-app campaigns. Leveraging MoEngage's data-driven customer insights, S'More can onboard customers and then analyze, segment, and send highly personalized messages that keep them coming back to make more meaningful connections. Read more >>
14Apr
Meet the FinTech Breakthrough Award Winners
2022 Winners - Personal Finance - Future Fuel, Best Personal Finance Platform. Read more >>
13Apr
Pyramid Biosciences Announces TIME Trial™ Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors
Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a range of serious diseases, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to strengthen and amplify identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial of Pyramid's lead oncology program PBI-200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor (PBI-200-101). Read more >>
13Apr